No, it may be they simply planned these as confirmation trials, and this would avoid having to do that later. You didn’t listen at all, it could be ECA acts sort of like a surrogate endpoint, in which case they may have planned on using these trials as confirmation trials. Instead of a weak idea, it would be a strong idea. If applicable. I talked about this possibility years ago.
Plus, now, as LP talks about, we can move onto tumor response/shrinkage very fast combo trials, and, imo, perhaps in dozens of indications, and we have no lingering trials to slow us down. We literally will have nothing pending when we (or whoever has the company then) start many new trials, imo.
Moreover, the current combos are small trials, and Merck is a sponsor of the blinded one, imo, preliminary analysis would be very short. Perhaps just a few weeks. It was unblinded to investigators September 11.
Market Data 
Markets 
AI
